Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

AIDS

Volumn 26, Issue 7, 2012, Pages 825-831

  Bedimo, Roger ^a,b   Maalouf, Naim M ^b   Zhang, Song ^b   Drechsler, Henning ^a,b   Tebas, Pablo ^c  

^a VA North Texas Health Care System   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cumulative exposure; osteoporotic fractures; protease inhibitors; tenofovir

Indexed keywords

ABACAVIR; ATAZANAVIR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; DIABETES MELLITUS; DISEASE REGISTRY; DRUG EXPOSURE; FRAGILITY FRACTURE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; VERTEBRA FRACTURE; WRIST FRACTURE;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIP FRACTURES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; RITONAVIR; SPINAL FRACTURES; TIME FACTORS; TREATMENT OUTCOME; WRIST INJURIES; YOUNG ADULT;

EID: 84862777752     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835192ae     Document Type: Article

References (28)

1. Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med 2007; 23:567-583; vii. (Pubitemid 47042341)
2. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145:397-406. (Pubitemid 46768570)
3. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998; 8:468-489. (Pubitemid 28486716)
4. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIVinfected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-F67. (Pubitemid 30182458)
5. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
6. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6:e17217.
7. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395-402.
8. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174. (Pubitemid 44684707)
9. McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH. CD4R cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005; 41:1662-1670. (Pubitemid 41691607)
10. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
11. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
12. Mulligan K, Glidden D, Gonzales P, Ramirez-Cardich M-E, Liu A, Namwongprom S, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the Gobal iPrEx study. In 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011.
13. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490. (Pubitemid 36241317)
14. Van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-1376.
15. Ofotokun I,Weitzmann N, Vunnava A, Sheth A, Villinger F, Zhou J, et al. HAART-induced immune reconstitution: a driving force behind bone resorption in HIV/AIDS. In 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011.
16. Van Vonderen MG, Mallon P, Murray B, Doran P, van Agtmael MA, Danner SA, et al. Changes in bone biomarkers in ARVna? ̈ve HIVRmen randomized to NVP/LPV/r or AZT/3TC/LPV/r help explain limited loss of bone mineral density over the first 12 months after ART initiation. In 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011.
17. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 166:241-246. (Pubitemid 43144951)
18. Womack J, Goulet J, Gibert CL, Brandt C, Mattocks K, Rimland D, et al. HIV-infection and fragility fracture risk among male veterans. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, California; 2010. pp. Abstract #129.
19. El-Maouche D, Mehta SH, Sutcliffe C, Higgins Y, Torbenson MS, Moore RD, et al. Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol 2011; 55:770-776.
20. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-1923. (Pubitemid 37070277)
21. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18:475-483. (Pubitemid 38365875)
22. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125:941-966. (Pubitemid 37070710)
23. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28:695-699. (Pubitemid 28405418)
24. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low-and high-energy fractures in persons with and without HIV-infection: a Danish population-based cohort study. AIDS 2012; 26:285-293.
25. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21:2473-2482. (Pubitemid 350145179)
26. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-946.
27. European AIDS Clinical Society Guidelines 2011, Version 6.0.
28. Rabenda V, Bruyere O, Reginster JY. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int 2011; 22:893-901.